8-K: Vivani Medical Secures $5 Million in Equity Financing, Advances GLP-1 Implant Program

Vivani Medical announced a $5 million equity financing, progress in its GLP-1 implant program, and reported third quarter 2024 financial results.

Summary

• Vivani Medical reported its third quarter 2024 financial results and provided a business update, including securing $5 million in equity financing.
• The company's miniature, ultra long-acting GLP-1 implant showed an 82% reduction in liver fat in an obese mouse model.
• Vivani received regulatory approval to initiate its first-in-human study in Australia, named LIBERATE-1, in the fourth quarter of 2024.
• The $5 million equity financing is expected to secure the company's financial position into late 2025, supporting the completion of the first-in-human study and data read-out.
• The company's NanoPortal drug delivery technology aims to address medication non-adherence, which is a significant issue in chronic disease management.
• Vivani's lead program, NPM-115, is a six-month GLP-1 implant for chronic weight management, and they are also developing NPM-139, a semaglutide implant with potential for once-yearly administration.
• The company's cash balance was $21.0 million as of September 30, 2024, compared to $26.3 million as of June 30, 2024.
• Research and development expenses for the third quarter of 2024 were $4.2 million, a slight decrease from $4.4 million in the same period of 2023.
• The net loss for the third quarter of 2024 was $6.0 million, an improvement from the $6.8 million loss in the third quarter of 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in the GLP-1 implant program and secured funding. However, the company is still operating at a loss and faces risks associated with clinical trials and regulatory approvals.

Positives

• The $5 million equity financing secures the company's financial position into late 2025.
• The company received regulatory approval to initiate its first-in-human study in Australia.
• Preclinical results for the GLP-1 implant showed significant liver fat reduction and comparable weight loss to semaglutide.
• The company's NanoPortal technology has the potential to address medication non-adherence.
• The net loss decreased by $0.8 million compared to the same quarter last year.

Negatives

• The company experienced a decrease in cash balance from $26.3 million to $21.0 million during the quarter.
• The company continues to operate at a loss, with a net loss of $6.0 million for the quarter.
• Research and development expenses remain high at $4.2 million for the quarter.

Risks

• The company is subject to risks related to the development and commercialization of its products, including potential delays in regulatory approvals.
• There are risks associated with the initiation, enrollment, and conduct of planned clinical trials.
• The company has a history of losses and may need to access additional capital to fund its business.
• Market conditions and the ability of Cortigent to complete its initial public offering pose additional risks.

Future Outlook

Vivani plans to initiate the LIBERATE-1 trial in the fourth quarter of 2024 and expects data from the trial to be available in 2025. The company also plans to continue development of its pipeline programs in 2025.

Management Comments

• Vivani's CEO, Adam Mendelsohn, stated that they made significant progress advancing their GLP-1 implants in the third quarter.
• Dr. Mendelsohn added that the $5 million financing puts them in an excellent position to complete LIBERATE-1 and continue development of their pipeline programs in 2025.
• Dr. Mendelsohn highlighted the potential of their NanoPortal technology to address medication non-adherence.

Industry Context

The announcement comes amid growing interest in GLP-1 therapies for obesity and type 2 diabetes. Vivani's long-acting implant technology aims to differentiate itself from existing daily or weekly injectable treatments by addressing medication adherence issues.

Comparison to Industry Standards

• The 82% liver fat reduction in mice is a strong preclinical result, comparable to or exceeding results seen with other GLP-1 agonists in similar models.
• The company's focus on long-acting implants addresses a key challenge in the GLP-1 market, which is patient adherence to daily or weekly injections, a problem also faced by companies like Novo Nordisk with their Ozempic and Wegovy products.
• The planned LIBERATE-1 trial will directly compare Vivani's implant to weekly semaglutide injections, providing a benchmark against an established treatment.

Related Party Transactions

• The company sold 3,968,253 shares of common stock to one of its independent directors at a price of $1.26 per share.

Stakeholder Impact

• Shareholders will benefit from the secured funding and progress in the GLP-1 implant program.
• Patients may benefit from the development of a long-acting implant that addresses medication non-adherence.
• Employees may benefit from the company's continued growth and development.

Next Steps

• Vivani plans to initiate the LIBERATE-1 clinical trial in the fourth quarter of 2024.
• The company will present at the Innovation in Obesity Therapeutics Summit in December 2024.
• Vivani will continue development of its pipeline programs in 2025.

Key Dates

Keywords

GLP-1 implant, obesity, weight management, exenatide, semaglutide, NanoPortal, drug delivery, clinical trial, medication adherence, biopharmaceutical